Immune cell populations in the tumour environment following calcium electropora-tion for cutaneous metastasis: a histopathological study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Immune cell populations in the tumour environment following calcium electropora-tion for cutaneous metastasis : a histopathological study. / Vissing, Mille; Sinius Pouplier, Sandra; Munch Larsen, Lars; Krog Frandsen, Stine; Lodin, Alexey; Lænkholm, Anne Vibeke; Gehl, Julie.

I: Acta oncologica (Stockholm, Sweden), Bind 63, 2024, s. 398-410.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Vissing, M, Sinius Pouplier, S, Munch Larsen, L, Krog Frandsen, S, Lodin, A, Lænkholm, AV & Gehl, J 2024, 'Immune cell populations in the tumour environment following calcium electropora-tion for cutaneous metastasis: a histopathological study', Acta oncologica (Stockholm, Sweden), bind 63, s. 398-410. https://doi.org/10.2340/1651-226X.2024.19462

APA

Vissing, M., Sinius Pouplier, S., Munch Larsen, L., Krog Frandsen, S., Lodin, A., Lænkholm, A. V., & Gehl, J. (2024). Immune cell populations in the tumour environment following calcium electropora-tion for cutaneous metastasis: a histopathological study. Acta oncologica (Stockholm, Sweden), 63, 398-410. https://doi.org/10.2340/1651-226X.2024.19462

Vancouver

Vissing M, Sinius Pouplier S, Munch Larsen L, Krog Frandsen S, Lodin A, Lænkholm AV o.a. Immune cell populations in the tumour environment following calcium electropora-tion for cutaneous metastasis: a histopathological study. Acta oncologica (Stockholm, Sweden). 2024;63:398-410. https://doi.org/10.2340/1651-226X.2024.19462

Author

Vissing, Mille ; Sinius Pouplier, Sandra ; Munch Larsen, Lars ; Krog Frandsen, Stine ; Lodin, Alexey ; Lænkholm, Anne Vibeke ; Gehl, Julie. / Immune cell populations in the tumour environment following calcium electropora-tion for cutaneous metastasis : a histopathological study. I: Acta oncologica (Stockholm, Sweden). 2024 ; Bind 63. s. 398-410.

Bibtex

@article{3ab1dfdf7d54401b9c203ec0e427a62d,
title = "Immune cell populations in the tumour environment following calcium electropora-tion for cutaneous metastasis: a histopathological study",
abstract = "BACKGROUND AND PURPOSE: Calcium electroporation (CaEP) involves injecting calcium into tumour tissues and using electrical pulses to create membrane pores that induce cell death. This study assesses resultant immune responses and histopathological changes in patients with cutaneous metastases. PATIENTS/MATERIALS AND METHODS: The aimed cohort comprised 24 patients with metastases exceeding 5 mm. Tumours were treated once with CaEP (day 0) or twice (day 28). Biopsies were performed on days 0 and 2, with additional samples on days 7, 28, 30, 35, 60, and 90 if multiple tumours were treated. The primary endpoint was the change in tumour-infiltrating lymphocytes (TILs) two days post-treatment, with secondary endpoints evaluating local and systemic immune responses via histopathological analysis of immune markers, necrosis, and inflammation. RESULTS: Seventeen patients, with metastases primarily from breast cancer (14 patients), but also lung cancer (1), melanoma (1), and urothelial cancer (1), completed the study. Of the 49 lesions treated, no significant changes in TIL count or PD-L1 expression were observed. However, there was substantial necrosis and a decrease in FOXP3-expression (p = 0.0025) noted, with a slight increase in CD4+ cells but no changes in CD3, CD8, or CD20 expressions. Notably, four patients showed reduced tumour invasiveness, including one case of an abscopal response. INTERPRETATION: This exploratory study indicates that CaEP can be an effective anti-tumour therapy potentially enhancing immunity. Significant necrosis and decreased regulatory lymphocytes were observed, although TIL count remained unchanged. Several patients exhibited clinical signs of immune response following treatment.",
author = "Mille Vissing and {Sinius Pouplier}, Sandra and {Munch Larsen}, Lars and {Krog Frandsen}, Stine and Alexey Lodin and L{\ae}nkholm, {Anne Vibeke} and Julie Gehl",
year = "2024",
doi = "10.2340/1651-226X.2024.19462",
language = "English",
volume = "63",
pages = "398--410",
journal = "Acta Oncologica",
issn = "1100-1704",
publisher = "Taylor & Francis",

}

RIS

TY - JOUR

T1 - Immune cell populations in the tumour environment following calcium electropora-tion for cutaneous metastasis

T2 - a histopathological study

AU - Vissing, Mille

AU - Sinius Pouplier, Sandra

AU - Munch Larsen, Lars

AU - Krog Frandsen, Stine

AU - Lodin, Alexey

AU - Lænkholm, Anne Vibeke

AU - Gehl, Julie

PY - 2024

Y1 - 2024

N2 - BACKGROUND AND PURPOSE: Calcium electroporation (CaEP) involves injecting calcium into tumour tissues and using electrical pulses to create membrane pores that induce cell death. This study assesses resultant immune responses and histopathological changes in patients with cutaneous metastases. PATIENTS/MATERIALS AND METHODS: The aimed cohort comprised 24 patients with metastases exceeding 5 mm. Tumours were treated once with CaEP (day 0) or twice (day 28). Biopsies were performed on days 0 and 2, with additional samples on days 7, 28, 30, 35, 60, and 90 if multiple tumours were treated. The primary endpoint was the change in tumour-infiltrating lymphocytes (TILs) two days post-treatment, with secondary endpoints evaluating local and systemic immune responses via histopathological analysis of immune markers, necrosis, and inflammation. RESULTS: Seventeen patients, with metastases primarily from breast cancer (14 patients), but also lung cancer (1), melanoma (1), and urothelial cancer (1), completed the study. Of the 49 lesions treated, no significant changes in TIL count or PD-L1 expression were observed. However, there was substantial necrosis and a decrease in FOXP3-expression (p = 0.0025) noted, with a slight increase in CD4+ cells but no changes in CD3, CD8, or CD20 expressions. Notably, four patients showed reduced tumour invasiveness, including one case of an abscopal response. INTERPRETATION: This exploratory study indicates that CaEP can be an effective anti-tumour therapy potentially enhancing immunity. Significant necrosis and decreased regulatory lymphocytes were observed, although TIL count remained unchanged. Several patients exhibited clinical signs of immune response following treatment.

AB - BACKGROUND AND PURPOSE: Calcium electroporation (CaEP) involves injecting calcium into tumour tissues and using electrical pulses to create membrane pores that induce cell death. This study assesses resultant immune responses and histopathological changes in patients with cutaneous metastases. PATIENTS/MATERIALS AND METHODS: The aimed cohort comprised 24 patients with metastases exceeding 5 mm. Tumours were treated once with CaEP (day 0) or twice (day 28). Biopsies were performed on days 0 and 2, with additional samples on days 7, 28, 30, 35, 60, and 90 if multiple tumours were treated. The primary endpoint was the change in tumour-infiltrating lymphocytes (TILs) two days post-treatment, with secondary endpoints evaluating local and systemic immune responses via histopathological analysis of immune markers, necrosis, and inflammation. RESULTS: Seventeen patients, with metastases primarily from breast cancer (14 patients), but also lung cancer (1), melanoma (1), and urothelial cancer (1), completed the study. Of the 49 lesions treated, no significant changes in TIL count or PD-L1 expression were observed. However, there was substantial necrosis and a decrease in FOXP3-expression (p = 0.0025) noted, with a slight increase in CD4+ cells but no changes in CD3, CD8, or CD20 expressions. Notably, four patients showed reduced tumour invasiveness, including one case of an abscopal response. INTERPRETATION: This exploratory study indicates that CaEP can be an effective anti-tumour therapy potentially enhancing immunity. Significant necrosis and decreased regulatory lymphocytes were observed, although TIL count remained unchanged. Several patients exhibited clinical signs of immune response following treatment.

U2 - 10.2340/1651-226X.2024.19462

DO - 10.2340/1651-226X.2024.19462

M3 - Journal article

C2 - 38804839

AN - SCOPUS:85194519356

VL - 63

SP - 398

EP - 410

JO - Acta Oncologica

JF - Acta Oncologica

SN - 1100-1704

ER -

ID: 394481046